Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: JAMA Otolaryngol Head Neck Surg. 2015 Oct;141(10):944–946. doi: 10.1001/jamaoto.2015.1762

Association of Hearing Impairment and Mortality in the National Health and Nutrition Examination Survey

Kevin J Contrera 1, Josh Betz 2, Dane J Genther 2,3, Frank R Lin 2,3,4
PMCID: PMC4803066  NIHMSID: NIHMS764746  PMID: 26401904

Hearing impairment (HI) is common in older adults. Its prevalence doubles with every decade of life, affecting two-thirds of adults older than 70 years.1 Hearing impairment has been shown to be associated with various negative health out-comes. The association of HI and mortality has been studied in select populations.2,3 We investigated the association of HI and all-cause mortality in a nationally representative sample of adults in the United States.

Methods

Using combined data from the January 1, 2005, to December 31, 2006, and January 1, 2009, to December 31, 2010, cycles of the National Health and Nutrition Examination Sur-vey (NHANES), we studied 1666 adults 70 years or older who had undergone audiometric testing. The NHANES is an ongoing epidemiologic study designed to assess the health of the US population using representative samples.4 The NHANES protocol was reviewed and approved by the National Center for Health Statistic's Institutional Review Board and in-formed written consent was obtained from all participants. Analysis was conducted from March 1 to May 1, 2015.

Severity of HI was defined per the World Health Organization criteria, based on the pure-tone average of hearing thresholds (in decibels) at speech frequencies (0.5-4 kHz) in the ear with better hearing (no HI, <25 dB; mild HI, ≥25 dB but <40 dB; moderate or more severe HI, ≥40 dB).5 Mortality was determined by probabilistic matching between NHANES data and death certificates from the National Death Index through December 31, 2011.6

Baseline characteristics of participants were compared using the χ2 test. The association between HI and mortality was analyzed using Cox proportional hazards regression models sequentially adjusted for demographic characteristics and cardiovascular risk factors known to be epidemiologically associated with HI. All analyses were weighted and conducted using the Stata statistical software program, version 12 (StataCorp LP).

Results

Compared with individuals without HI (n = 527), individuals with HI (n = 1139) were more likely to be older, male, white, former smokers, less educated, and have a history of cardiovascular disease and stroke (Table 1). In the age-adjusted model, moderate or more severe HI was associated with a 54% increased risk of mortality (hazard ratio [HR], 1.54; 95% CI, 1.08-2.18) and mild HI with a 27% increased risk of mortality (HR, 1.27; 95% CI, 0.83-1.95), compared with individuals without HI (Table 2). After further adjustment for demo-graphic characteristics and cardiovascular risk factors, our results suggest that HI may be associated with a 39% (HR, 1.39;95% CI, 0.97-2.01) and 21% (HR, 1.21; 95% CI, 0.81-1.81) in-creased risk of mortality in individuals with moderate or more severe HI and mild HI, respectively, compared with individuals without HI. Analysis restricted to individuals 80 years or younger (in whom age could be adjusted for precisely) yielded results also suggestive of a positive association between HI and mortality.

Table 1.

Characteristics of Participants by Category of Hearing Categorya

Hearing Impairment, No. (%)
Characteristics None (n =527) Mild (n = 589) Moderate or More Severe (n = 550) P Value
Age, y
    70-74 288 (54.6) 212 (36.0) 107 (19.5) <.001
    75-79 137 (26.0) 155 (26.3) 127 (23.1)
    ≥80 102 (19.4) 222 (37.7) 316 (57.5)

Sex
    Male 217 (41.2) 286 (48.6) 344 (62.5) <.001
    Female 310 (58.8) 303 (51.4) 206 (37.5)

Race
    White 327 (62.1) 427 (72.5) 432 (78.6) <.001
    Black 117 (22.2) 77 (13.1) 40 (7.3)
    Hispanic 67 (12.7) 69 (11.7) 62 (11.3)
    Other 16 (3.0) 16 (2.7) 16 (2.9)

Education
    Less than high school 160 (30.4) 201 (34.1) 226 (41.1) <.001
    High school graduate 128 (24.3) 175 (29.7) 125 (22.7)
    Some College 238 (45.2) 213 (36.2) 197 (35.8)
    Refused or not known 1 (0.2) 0 2 (0.4)

Smoking status
    Never 257 (48.8) 287 (48.7) 246 (44.7) 0.039
    Former 225 (42.7) 254 (43.1) 275 (50.0)
    Current 45 (8.5) 48 (8.1) 29 (5.3)

Cardiovascular diseaseb 103 (19.5) 153 (26.0) 154 (28.0) 0.004

Hypertension 351 (66.6) 372 (63.2) 330 (60.0) 0.080

Diabetes mellitus 112 (21.3) 141 (23.9) 105 (19.1) 0.136

Stroke history 38 (7.2) 62 (10.5) 68 (12.4) 0.018

All-cause mortality 55 (10.4) 85 (14.4) 112 (20.4) <.001
a

Hearing impairment is defined by the speech frequency pure-tone average of thresholds at 0.5, 1, 2, and 4 kHz in the better hearing ear (no impairment <25 dB, mild 25 to <40 dB, moderate or severe impairment ≥ 40dB).

b

Includes history of myocardial infarction, history of angina, diagnosis of coronary artery disease, diagnosis of congestive heart failure.

Table 2.

Adjusted Risk of Mortality by Category of Hearing Impairmenta

Cox Proportional Hazards Regression Model Hazard Ratio (95% CI)
No Hearing Impairment Mild Hearing Impairment Moderate or More Severe Hearing Impairment
Base ref 1.54 (1.06, 2.25) 2.3 (1.64, 3.27)
Base + age ref 1.27 (0.83, 1.95) 1.54 (1.08, 2.18)
Base + age, sex, race, education ref 1.27 (0.87, 1.87) 1.41 (0.99, 2.02)
Base + Demographic + Cardiovascular Factors (stroke, smoking, diabetes, hypertension, cardiovascular diseaseb) ref 1.21 (0.81, 1.81) 1.39 (0.97, 2.01)
a

Hearing impairment is defined by the speech frequency pure-tone average of thresholds at 0.5, 1, 2, and 4 kHz in the better hearing ear (no impairment <25 dB, mild 25 to <40 dB, moderate or severe impairment ≥ 40dB).

b

Includes history of myocardial infarction, history of angina, diagnosis of coronary artery disease, diagnosis of congestive heart failure.

Discussion

In this nationally representative sample of adults 70 years or older, moderate or more severe HI was significantly associated with a 54% increased risk of mortality after adjustment for age, although this association was attenuated after adjustment for demographics and cardiovascular factors. We observed a dose-response association, with greater HI being associated with a greater risk of mortality. To our knowledge, this report is the first to investigate the association between HI and mortality in a nationally representative US sample.

Our results are generally comparable with those of previous studies.2,3 Potential mechanisms for these findings include causal (or plausibly bidirectional) connections of HI with cognitive, mental, and physical function. A limitation of this study is that the size of our analytic cohort and duration of follow-up may have limited the power to detect significant associations in our fully adjusted models compared with those of previous studies.2,3 In addition, age was treated as a categorical covariate instead of as the time scale in the Cox analysis, which was necessary because NHANES truncates age at 80 years for confidentiality purposes. This parameterization of age may result in residual confounding owing to the inability to precisely adjust for differences in age.

Future studies are required to explore the basis of the association of HI with mortality and to determine whether therapies to rehabilitate hearing can reduce mortality.

Acknowledgments

Funding: This manuscript was supported in part by the Johns Hopkins Institute for Clinical and Translational Research, NIH TL1 TR001078, NIH K23DC011279, the Eleanor Schwartz Charitable Foundation, and a Triological Society/American College of Surgeons Clinician Scientist Award. Funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Its contents are solely the responsibility of the authors.

Footnotes

Authors’ Contributions: Kevin J. Contrera: (1) conception of the design, conduction of the analysis, (2) drafting the manuscript, (3) approval of the final manuscript, (4) agreement to be accountable for all aspects of the work

Josh Betz: (1) conduction of the analysis, (2) critical revision of the manuscript, approval of the final manuscript, (4) agreement to be accountable for all aspects of the work

Dane J. Genther: (1) conduction of the analysis, (2) critical revision of the manuscript, (3) approval of the final manuscript, (4) agreement to be accountable for all aspects of the work

Frank R. Lin: (1) conception of the design, (2) critical revision of the manuscript, (3) approval of the final manuscript, (4) agreement to be accountable for all aspects of the work

Kevin J. Contrera had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Disclosures: Dr. Frank Lin reports being a consultant to Cochlear, on the scientific advisory board for Autifony and Pfizer, and a speaker for Med El and Amplifon

References

RESOURCES